Comparative Pharmacology
Head-to-head clinical analysis: MAXIDEX versus PREDNISOLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXIDEX versus PREDNISOLONE.
MAXIDEX vs PREDNISOLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAXIDEX (dexamethasone) is a potent glucocorticoid that binds to the glucocorticoid receptor (GR), leading to modulation of gene expression and inhibition of inflammatory mediators such as prostaglandins and leukotrienes. It suppresses immune response through inhibition of cytokine production (e.g., IL-1, IL-2, TNF-alpha) and reduces vasodilation and vascular permeability.
Prednisolone is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, inhibition of phospholipase A2, and reduction of prostaglandin and leukotriene synthesis.
One to two drops of the 0.1% ophthalmic suspension into the conjunctival sac every hour during the day and every two hours at night initially; after improvement, reduce to one drop every four hours, then one drop three to four times daily.
Initial adult dose: 5-60 mg orally, intramuscularly, or intravenously daily, divided into 2-4 doses; maintenance: 2.5-15 mg daily.
None Documented
None Documented
Clinical Note
moderatePrednisolone + Digoxin
"Prednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethylprednisolone + Digoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePrednisolone + Digitoxin
"Prednisolone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethylprednisolone + Digitoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is approximately 2-3 hours for dexamethasone; in ocular tissues, half-life may be prolonged due to local retention, but systemic half-life is short with minimal accumulation.
Terminal half-life: 2.1-3.5 hours in adults; prolonged in hepatic impairment (up to 12 hours) or with concurrent estrogen use.
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for <15% unchanged drug; biliary/fecal elimination of metabolites predominates.
Renal (primarily as glucuronide and sulfate conjugates; <20% as unchanged prednisolone); biliary/fecal (minor, <5%).
Category C
Category D/X
Corticosteroid
Corticosteroid